Share Purchase Plan and Options Offer Open
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Share Purchase Plan and Options Offer Open
Not for release to US wire services or distribution in the United States
16 November 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon”
or “the Company”), a late clinical-stage biotechnology company dedicated to advancing innovative treatments for
neurodegenerative diseases announced on Monday, 2 November 2026 that it had received firm commitments to
raise A$4.3 million (before costs) through the issue of 63.2 million new fully paid ordinary shares (“Shares”) (the
“New Shares”) at A$0.068 per New Share (“Placement Offer Price”) (the “Placement”). The Placement includes a
A$150,000 commitment from the Company’s Board and management (with Director participation subject to
shareholder approval). The Company also announced that it will offer Eligible Shareholders the opportunity to
participate in a Share Purchase Plan (“SPP”) which targets to raise an additional A$2.0 million.
Participants in both the Placement and SPP will each be entitled to be made an offer, subject to shareholder
approval, to apply to receive (for no consideration) one new option (“New Option”) for each New Share issued under
the Placement or subscribed for under the SPP (as applicable), exercisable at A$0.12 and expiring 18 months from
issue. Subject to satisfying spread requirements set out in ASX Listing Rule 2.5, condition 6, the New Options are
intended to be quoted on the ASX and the issue of New Options is subject to such quotation. The New Options will
be offered to eligible participants via a prospectus lodged with the Australian Securities and Investments
Commission (“ASIC”) and to be released to ASX today.
Funds raised under the Placement and SPP, together with existing cash (following the redemption of all outstanding
convertible notes then held by Obsidian Global GP, LLC) and anticipated R&D tax incentive refunds, will be applied
to:
Clinical and pre-clinical activities, including completion of Regimen I of the Phase 2/3 HEALEY ALS Platform
Trial, with topline results anticipated in late Q2 CY2027;
Manufacturing, supply-chain readiness and regulatory activities to support the continued clinical
development and preparation for potential commercialisation of NUZ-001;
Market engagement and business development activities, including potential strategic partnering
opportunities; and
Corporate costs (commercial, finance and governance), working capital and transaction expenses.
The SPP will open at 9.00am (Melbourne time) today, Monday, 16 November 2026, to “Eligible Shareholders”, being
persons who were registered holders of Shares in Neurizon at 7.00pm Friday, 30 October 2026, with a registered
address in Australia or New Zealand at that time as shown on the share register, who are not in the United States
and are not acting for the account or benefit of a person in the United States (and who meet certain other eligibility
criteria), to apply for up to A$30,000 worth of New Shares at an issue price of A$0.068 per New Share (i.e. the same
price as the Placement Offer Price) (“SPP Offer”). New Shares issued in the Placement are not eligible to participate
in the SPP.
The SPP is being offered to Eligible Shareholders to extend an opportunity to invest on the same terms as the
institutional and sophisticated investors who participated in the Placement. The SPP will enable Eligible
Shareholders, irrespective of the size of their holding, to apply to participate in the capital raising at the same price
as the Placement Offer Price, and not incur any brokerage or transaction costs. Participation in the SPP is optional.
Chief Executive Officer, Dr Chris Bremer, said: “We are pleased to offer our existing shareholders the opportunity to
participate in this capital raising on the same terms as the investors in the Placement, at the same price, with no
brokerage, and being entitled to be made an offer, subject to shareholder approval, to apply to receive (for no
consideration) one New Option for each share subscribed for under the SPP.
Our shareholders have supported Neurizon through an important period. With the Phase 2/3 HEALEY ALS Platform
Trial fully recruited, topline results anticipated in late Q2 CY2027, and no convertible notes on issue, the SPP gives
them the opportunity to participate as we approach this key milestone. Strong participation in the SPP would also
strengthen our funding position and may reduce the need to draw further on the Obsidian facility.”
The SPP is targeting to raise A$2 million. Neurizon may (in its absolute discretion) in a situation where total demand
exceeds A$2 million, decide to increase the amount to be raised under the SPP to reduce or eliminate the need for
scale back. Neurizon reserves the right to scale back applications at its absolute discretion.
The SPP is not underwritten.
New Shares issued under the SPP will rank equally with existing fully paid ordinary shares then on issue.
As stated above, participants under the SPP will be entitled to be made a separate offer by the Company, subject to
shareholder approval, to apply to receive (for no consideration) 1 New Option for every 1 New Share subscribed for
under the SPP (rounded down to the nearest whole number) on the same terms as participants under the Placement
(“SPP Options Offer”).
SPP booklet and prospectus
The SPP is subject to the terms and conditions set out in the SPP booklet (a copy of which is attached). The New
Options will be offered to Eligible Shareholders via a prospectus lodged with ASIC and to be released to ASX today.
Eligible Shareholders who have provided an email address will be sent an email communication with details of how
to obtain a copy of the SPP booklet, prospectus and their personalised application form (a sample of which is
attached). Eligible Shareholders who have not provided an email address will be sent an SPP and New Options offer
letter (a sample of which is attached) via post with details of how to obtain a copy of the SPP booklet, prospectus
and their personalised application form. The SPP booklet, prospectus and personalised application forms are also
available at: https://portal.automic.com.au/investor/home.
Eligible Shareholders are encouraged to read the SPP booklet and prospectus carefully, and if in any doubt about
whether or not to accept the SPP Offer and SPP Options Offer, to consult with a financial or other professional
adviser.
The SPP Offer and SPP Options Offer are each expected to close at 5.00pm (Melbourne time) on Friday, 4 December
2026 (unless extended, withdrawn or closed early by the Company). To apply for New Shares under the SPP, Eligible
Shareholders must, by 5.00pm (Melbourne time) on Friday, 4 December 2026, make a payment directly via BPAY®
or electronic funds transfer in accordance with the instructions on their personalised application form. The SPP
Options Offer application form will be part of the application form for participation in the SPP Offer. SPP participants
are not required to separately return the SPP Options Offer application form. By applying for New Shares in
accordance with the SPP Offer (including by paying the application monies for New Shares in accordance with the
instructions on that application form) SPP participants will also be applying for New Options under the SPP Options
Offer on the terms of the SPP Options Offer application form and the prospectus.
Shareholders with questions in relation to how to participate in the SPP Offer and SPP Options Offer should contact
Neurizon’s share registry, Automic, from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public
holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers outside Australia) or
email corporate.actions@automicgroup.com.au during the offer period or consult their financial or other
professional adviser.
INDICATIVE OFFER TIMETABLE1
Event Dates (Melbourne time)
SPP record date 7.00pm, Friday, 30 October 2026
SPP opening date and New Options offer opening date
9.00am, Monday, 16 November
2026
SPP Offer and SPP Options Offer closing date
5.00pm, Friday, 4 December
2026
Results of SPP announced Friday, 11 December 2026
Issue of New Shares under SPP Friday, 11 December 2026
New Shares under SPP commence trading on ASX Monday, 14 December 2026
Despatch of holding statements in respect of SPP New Shares Tuesday, 15 December 2026
General Meeting to approve Director participation and the New Options Thursday, 17 December 2026
Issue of New Shares under Director participation2 Monday, 21 December 2026
Placement options offer closing date
5.00pm, Monday, 21 December
2026
Expected normal trading of New Shares under Director Participation and
issue of New Options under Placement and SPP2
Tuesday, 22 December 2026
Expected commencement of normal trading of New Options on ASX2
Wednesday, 23 December 2026
1. The above timetable is indicative only. The Company reserves the right to close the SPP early, extend the SPP closing date or to withdraw the
SPP, in its sole and absolute discretion, by lodging an announcement with the ASX. The closing date of the SPP Options Offer is the same closing
date as the SPP Offer. Any change to the closing date of the SPP will also change the closing date of the SPP Options Offer. The commencement
of trading and quotation of New Shares and New Options is subject to ASX confirmation. The Company gives no assurance that such quotation
will be granted.
2. Subject to shareholder approval being obtained at the General Meeting and quotation condition being satisfied (as applicable).
-ENDS-
This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.
This announcement has been prepared for publication in Australia and may not be released to US wire services or
distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer
to buy, any securities in the United States or in any other jurisdiction in which such offer or solicitation would be
unlawful. The securities described in this announcement have not been, and will not be, registered under the US
Securities Act of 1933, as amended (the "US Securities Act"), or the securities laws of any state or other jurisdiction
of the United States, and may not be offered or sold in the United States except in a transaction exempt from, or
not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.
For further information, please contact:
Marketing & Corporate Affairs
Lidija Damjanovic
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504
Investor Relations
Henry Jordan
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader
neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an
investigational product and is not approved for commercial use in any jurisdiction.
Neurizon Investor Hub
We encourage you to utilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and
view video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Neurizon Therapeutics Limited
Share Purchase Plan Booklet
This is an important document and requires your immediate attention. You should read this Booklet
in full.
Eligible Shareholders have the opportunity to participate in the Share Purchase Plan offer by
applying for up to $30,000 worth of new Shares without incurring brokerage or other transaction
costs. Details of the offer and how to participate are set out in this Booklet.
Participants under the SPP will be entitled to be made a separate offer by the Company, subject to
Shareholder approval at the General Meeting, to apply to receive (for no consideration) 1 new
Option for every 1 SPP Share subscribed for under the SPP (rounded down to the nearest whole
number). Subject to satisfying spread requirements set out in Listing Rule 2.5, condition 6, the new
Options are intended to be quoted on the ASX and the issue of new Options is subject to such
quotation. The new Options are not offered under this Booklet. The new Options will be offered
under a separate prospectus.
Applications for SPP Shares under the SPP Offer must be received by 5.00pm (Melbourne
time) on Friday, 4 December 2026.
This Booklet is dated 16 November 2026.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 1
Table of contents
1 Letter to Shareholders 1
2 Summary of important dates 4
3 Summary of SPP 5
4 SPP Terms and Conditions 10
4.1 Offer .................................................................................................................. 10
4.2 Eligible Shareholders ...................................................................................... 11
4.3 Joint holders and Custodians ........................................................................ 11
4.4 Applications for SPP Shares .......................................................................... 12
4.5 Issue Price........................................................................................................ 13
4.6 Number of SPP Shares to be issued ............................................................. 14
4.7 Issue of SPP Shares ........................................................................................ 14
4.8 Shareholders outside Australia...................................................................... 14
4.9 Representations, warranties and acknowledgements................................. 14
4.10 Scale back ........................................................................................................ 18
4.11 Dispute resolution ........................................................................................... 18
4.12 Variation and termination ............................................................................... 18
4.13 Privacy policy................................................................................................... 19
4.14 ASIC Corporations Instrument compliance .................................................. 19
4.15 Underwriting..................................................................................................... 19
4.16 Governing law .................................................................................................. 19
5 Glossary 20
Important information
This Booklet is intended for use only in connection with the SPP Offer to Eligible
Shareholders. This Booklet does not constitute an offer of securities in any place outside
Australia or New Zealand and no action has been taken to permit an offering of Shares in
any jurisdiction outside of Australia and New Zealand. The distribution of this Booklet is
restricted by law and persons (including Custodians) who come into possession of this
document should observe any such restrictions. Due to legal restrictions, Custodians may
not distribute this Booklet or any other document relating to the SPP, and may not permit
any beneficial Shareholder to participate in the SPP, in any country outside Australia or
New Zealand.
This Booklet may not be distributed or released in the United States (U.S.). This Booklet
does not constitute an offer to sell, or a solicitation of an offer to buy, any Shares in the
U.S. or in any jurisdiction in which such an offer would be illegal. The Shares to be
offered and sold under the SPP Offer have not been, and will not be, registered under the
U.S. Securities Act of 1933, as amended (Securities Act), or the securities laws of any
U.S. state or other jurisdiction of the U.S., and may not be offered or sold, directly or
indirectly, to persons in the U.S. or to any person acting for the account or benefit of a
person in the U.S. (to the extent such person is acting for the account or benefit of a
person in the U.S.) except pursuant to an exemption from the registration requirements of
the Securities Act and applicable state securities laws.
Participants under the SPP will be entitled to be made a separate offer by the Company,
subject to Shareholder approval at the General Meeting, to apply to receive (for no
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 2
consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP
(rounded down to the nearest whole number). Subject to satisfying spread requirements
set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the
ASX and the issue of new Options is subject to such quotation. The new Options are not
offered under this Booklet. The new Options will be offered to eligible participants via a
prospectus expected to be lodged with ASIC and released to ASX on or around Monday,
16 November 2026.
The SPP Offer is not a recommendation to acquire Shares. This document does not
constitute financial product advice and does not take into account the individual
investment objectives, financial situation or particular needs of each Eligible Shareholder.
Eligible Shareholders wanting to participate in the SPP should obtain independent advice
in relation to the taxation and other consequences of an investment under the SPP before
making a decision as to whether to participate in the SPP. A cooling-off regime does not
apply in relation to the acquisition of Shares under the SPP.
This Booklet does not purport to include or summarise all information that an investor
should consider when making an investment decision, nor does it contain all information
which would be required in a prospectus, product disclosure statement or other
disclosure document prepared in accordance with the Corporations Act or any other
applicable law. This Booklet should be read in conjunction with Neurizon’s periodic and
continuous disclosure announcements lodged with the ASX which are available at
www.asx.com.au.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 1
1 Letter to Shareholders
Dear Shareholder
On behalf of the directors of Neurizon Therapeutics Limited (Neurizon or the Company),
I am pleased to offer you the opportunity to participate in the Neurizon Share Purchase
Plan (SPP), which allows Eligible Shareholders to subscribe for up to $30,000 worth of
new Shares in Neurizon (SPP Shares) without incurring brokerage or other transaction
costs.
The SPP aims to raise $2 million and is not underwritten.
Neurizon reserves the right to determine the aggregate amount it raises through the SPP.
If total demand exceeds $2 million, Neurizon may decide to increase the amount to be
raised under the SPP to reduce or eliminate the need for scale back. Neurizon may, in its
absolute discretion, scale back the number of SPP Shares that will be issued to individual
Eligible Shareholders under the SPP Offer to the extent, and in the manner, it sees fit.
The SPP follows Neurizon’s successful placement, announced on Monday, 2 November
2026, which raised $4.3 million (before costs) (Placement), including participation by
Directors of $100,000 in aggregate, subject to Shareholder approval at a general meeting
expected to be held on or around Thursday, 17 December 2026 (General Meeting).
The SPP Shares are being offered at the Issue Price of $0.068 per SPP Share, being the
same offer price as that under the Placement.1
For completeness, participants under the Placement will be entitled to be made an offer
by the Company, subject to Shareholder approval at the General Meeting, to apply to
receive (for no consideration) 1 new Option for every 1 new Share issued under the
Placement (rounded down to the nearest whole number). Subject to satisfying spread
requirements set out in Listing Rule 2.5, condition 6, the new Options are intended to be
quoted on the ASX and the issue of new Options is subject to such quotation. The new
Options will be offered to eligible participants via a prospectus expected to be lodged with
ASIC and released to ASX on or around Monday, 16 November 2026.
In addition, participants under the SPP will be entitled to be made a separate offer by the
Company, subject to Shareholder approval at the General Meeting, to apply to receive
(for no consideration) 1 new Option for every 1 SPP Share subscribed for under the SPP
(rounded down to the nearest whole number). Subject to satisfying spread requirements
set out in Listing Rule 2.5, condition 6, the new Options are intended to be quoted on the
ASX and the issue of new Options is subject to such quotation. The new Options are not
offered under this Booklet. The new Options will be offered to eligible participants via a
prospectus expected to be lodged with ASIC and released to ASX on or around Monday,
16 November 2026.
Use of proceeds
Funds raised under the Placement and SPP, together with existing cash (following the
redemption of all outstanding convertible notes then held by Obsidian Global GP, LLC)
and anticipated R&D tax incentive refunds, will be applied to:
clinical and pre-clinical activities, including completion of Regimen I of the
Phase 2/3 HEALEY ALS Platform Trial, with topline results anticipated in late
Q2 CY2027;
1
Represents:
a 20.9% discount to the closing price of Shares traded on 28 October 2026 being the last trading
day prior to the Company entering a two day trading halt to conduct the Placement;
an 18.9% discount to the 5-day VWAP up to and including 28 October 2026 being the last trading
day prior to the Company entering a two day trading halt to conduct the Placement (excluding 28
October 2026 as no sales in Shares were recorded on that day); and
a 19.3% premium to the closing price of $0.057 as at 12 November 2026.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 2
manufacturing, supply-chain readiness and regulatory activities to support the
continued clinical development and preparation for potential commercialisation
of NUZ-001;
market engagement and business development activities, including potential
strategic partnering opportunities; and
corporate costs (commercial, finance and governance), working capital and
transaction expenses.
Further details about the Placement and the SPP, including a summary of some of the
key risks associated with holding an investment in Neurizon, are included in Neurizon’s
ASX announcement released on Monday, 2 November 2026, which we encourage you to
read. You can view this ASX announcement at www.asx.com.au (ASX: NUZ) and
Neurizon’s website: https://investorhub.neurizon.com/announcements.
Participation in the SPP
Participation in the SPP is voluntary and open to all Eligible Shareholders, being persons
who were registered holders of Shares in Neurizon at 7.00pm (Melbourne time) on
Friday, 30 October 2026 (Record Date), with a registered address in either Australia or
New Zealand at that time as shown on the Register (and who meet certain other eligibility
criteria). The SPP Offer is also being extended to Eligible Shareholders who are
Custodians to participate in the SPP on behalf of certain Eligible Beneficiaries on the
Terms and Conditions set out in this Booklet.
Persons in the United States are not eligible to participate in the SPP. Similarly, persons
(including Custodians) who hold Shares on behalf of persons who reside outside
Australia or New Zealand (including the United States) or are acting for the account or
benefit of persons in the United States, are not eligible to participate in the SPP on behalf
of those persons.
Once issued, SPP Shares will rank equally with existing Shares in Neurizon.
The terms and conditions of the SPP are provided in this Booklet. We urge you to read
these materials in their entirety and seek your own financial and taxation advice in
relation to the SPP, before you decide whether to participate.
How to apply for SPP Shares
To apply for SPP Shares, please follow the instructions in your personalised Application
Form. Your personalised Application Form can be accessed via
https://portal.automic.com.au/investor/home. In accordance with the instruction in your
personalised Application Form, you must either:
make a payment directly via BPAY®2, which is the fastest and easiest way to
apply. For completeness, you can only make payment via BPAY if you are the
holder of an account with an Australian branch of a financial institution that
supports BPAY transactions; or
pay for SPP Shares by making an electronic funds transfer (EFT).
Cheque, bank draft, money order and cash payments will not be accepted.
Eligible Shareholders wishing to apply for SPP Shares must ensure that their payment is
received by no later than 5.00pm (Melbourne time) on Friday, 4 December 2026.
2
Registered by BPAY Pty Ltd (ABN 69 079 137 518).
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 3
Questions and further information
This Booklet contains important information about the SPP to assist you in deciding
whether to participate in the SPP. You should read this Booklet carefully and in its
entirety before deciding whether to apply.
If you have any questions in relation to how to participate in the SPP, please contact the
Registry from 8.30am to 7.00pm (Melbourne time) Monday to Friday (excluding public
holidays) on 1300 288 664 (for callers within Australia) or +61 2 9698 5414 (for callers
outside Australia) or email corporate.actions@automicgroup.com.au during the Offer
Period, or consult your financial or other professional adviser. If you have any questions
in relation to whether an investment in Neurizon through the SPP Offer is appropriate for
you, please contact your stockbroker, accountant or other professional adviser.
Thank you for your continued support of Neurizon.
Yours sincerely
Sergio Duchini
Chair
Neurizon Therapeutics Limited
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 4
2 Summary of important dates
Event Date
Record Date (the date that eligibility to participate in the SPP
was determined)
7.00pm (Melbourne time),
Friday, 30 October 2026
Opening Date for applications 9.00am (Melbourne time),
Monday, 16 November 2026
Closing Date for applications 5.00pm (Melbourne time),
Friday, 4 December 2026
Results of SPP announced Friday, 11 December 2026
Issue of SPP Shares Friday, 11 December 2026
SPP Shares commence trading on ASX Monday, 14 December 2026
Despatch of holding statements Tuesday, 15 December 2026
General Meeting Thursday, 17 December 2026
This timetable is indicative only and subject to change. Neurizon reserves the right to alter the
dates above at its discretion, subject to the Listing Rules and Corporations Act. All references to
times in this Booklet are to Melbourne time.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
page 5
3 Summary of SPP
You should read this section in conjunction with the Terms and Conditions set out in
section 4 of this Booklet.
Key SPP details Summary
SPP Offer Eligible Shareholders of Neurizon may subscribe for up to $30,000
worth of SPP Shares without brokerage or other transaction costs.
Purpose of the SPP Funds raised under the Placement and SPP, together with existing
cash (following the redemption of all outstanding convertible notes then
held by Obsidian Global GP, LLC) and anticipated R&D tax incentive
refunds, will be applied to:
clinical and pre-clinical activities, including completion of Regimen I
of the Phase 2/3 HEALEY ALS Platform Trial, with topline results
anticipated in late Q2 CY2027;
manufacturing, supply-chain readiness and regulatory activities to
support the continued clinical development and preparation for
potential commercialisation of NUZ-001;
market engagement and business development activities, including
potential strategic partnering opportunities; and
corporate costs (commercial, finance and governance), working
capital and transaction expenses.
For further information, refer to the Company’s ASX announcement
dated 2 November 2026.
Voluntary participation Participation in the SPP is entirely voluntary.
Before you decide whether to participate in the SPP, Neurizon
recommends you seek independent financial advice from your
stockbroker, accountant or other professional adviser.
If you do not wish to participate in the SPP, no further action is
required on your part.
Issue Price of the SPP
Shares
The Issue Price of the SPP Shares is $0.068 per SPP Share, being the
same offer price as that under the Placement.3
3
Represents:
a 20.9% discount to the closing price of Shares traded on 28 October 2026 being the last trading
day prior to the Company entering a two day trading halt to conduct the Placement;
an 18.9% discount to the 5-day VWAP up to and including 28 October 2026 being the last trading
day prior to the Company entering a two day trading halt to conduct the Placement (excluding 28
October 2026 as no sales in Shares were recorded on that day); and
a 19.3% premium to the closing price of $0.057 as at 12 November 2026.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 3 Summary of SPP
page 6
Key SPP details Summary
There is a risk that the market pri
Share your feedback
Discover